Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment

Chris H. Polman, S. C. Reingold, F. Barkhof, P. A. Calabresi, M. Clanet, J. A. Cohen, G. R. Cutter, M. S. Freedman, L. Kappos, F. D. Lublin, H. F. McFarland, L. M. Metz, A. E. Miller, X. Montalban, P. W. O'Connor, H. Panitch, J. R. Richert, J. Petkau, S. R. Schwid, M. P. SormaniA. J. Thompson, B. G. Weinshenker, J. S. Wolinsky

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


The increasing number of established effective therapies for relapsing multiple sclerosis (MS) and emerging consensus for early treatment raise practical concerns and ethical dilemmas for placebo-controlled clinical trials in this disease. An international group of clinicians, ethicists, statisticians, regulators, and representatives from the pharmaceutical industry convened to reconsider prior recommendations regarding the ethics of placebo-controlled trials in MS. The group concluded that placebo-controlled trials can still be done ethically, with restrictions. For patients with relapsing MS for which established effective therapies exist, placebo-controlled trials should only be offered with rigorous informed consent if the subjects refuse to use these treatments, have not responded to them, or if these treatments are not available to them for other reasons (e.g., economics). Suggestions are provided to protect subject autonomy and improve informed consent procedures. Recommendations are tighter than previously suggested for placebo-controlled trials in "resource-restricted" environments where established therapies may not be available. Guidance is also provided on the ethics of alternative trial designs and the balance between study subject burden and risk, scientific rationale and interpretability of trial outcomes.

Original languageEnglish (US)
Pages (from-to)1134-1140
Number of pages7
Issue number13 PART 2
StatePublished - Mar 2008

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment'. Together they form a unique fingerprint.

Cite this